← The Wire
TARSNasdaq
Tarsus Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · DE · CIK 1819790
Develops and commercializes eye care therapeutics, starting with Demodex blepharitis treatment
$2.67B
Market cap
$61.26
Last close
-2.6%
1D
-3.6%
5D
980K
Volume
Price · last 39 sessions-5.1%
May 4L $57.41 · H $67.11Jun 29
129
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 29, 202610-Q10-QMay 6, 20268-KResults of OperationsMay 6, 2026DEFA14ADEFA14AApr 28, 2026DEF 14ADEF 14AApr 28, 202610-K10-KFeb 23, 20268-KResults of OperationsFeb 23, 20268-KExecutive ChangeFeb 18, 20268-KReg FD DisclosureJan 12, 202610-Q10-QNov 4, 20258-KResults of OperationsNov 4, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 6, 20258-KShareholder VoteJun 18, 202510-Q10-QMay 1, 20258-KResults of OperationsMay 1, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 20258-KCompany UpdateMar 18, 20258-KMaterial Agreement · Company UpdateMar 13, 2025424B5424B5Mar 13, 2025424B5424B5Mar 12, 202510-K10-KFeb 25, 20258-KResults of OperationsFeb 25, 20258-KExecutive ChangeJan 17, 20258-KReg FD DisclosureJan 13, 20258-KMaterial AgreementDec 19, 202410-Q10-QNov 13, 20248-KResults of OperationsNov 13, 2024SC 13GTARS09302024 13GNov 12, 20248-KExecutive ChangeNov 5, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KShareholder VoteJun 18, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 20248-KMaterial Agreement · New Debt / ObligationApr 23, 20248-KCompany UpdateMar 5, 20248-KMaterial Agreement · Company UpdateMar 1, 2024424B5424B5Mar 1, 2024424B5424B5Feb 29, 202410-K10-KFeb 27, 20248-KResults of OperationsFeb 27, 2024SC 13GMS INITIALFeb 9, 2024SC 13GSC 13GJan 26, 2024SC 13GSC 13GJan 22, 20248-KExecutive ChangeJan 18, 20248-KReg FD DisclosureJan 8, 20248-KCompany UpdateDec 11, 20238-KResults of OperationsNov 9, 202310-Q10-QNov 9, 202310-Q10-QAug 10, 20238-KResults of OperationsAug 10, 20238-KMaterial Agreement · Company UpdateAug 2, 2023424B5424B5Aug 2, 2023424B5424B5Jul 31, 20238-KCompany UpdateJul 31, 20238-KReg FD DisclosureJul 25, 20238-KShareholder VoteJun 27, 20238-KReg FD DisclosureJun 15, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023SC 13GCOWEN FINANCIAL PRODUCTS LLCMay 5, 2023DEFA14ADEFA14AApr 26, 2023DEF 14ADEF 14AApr 26, 20238-KExecutive ChangeApr 24, 202310-K10-KMar 17, 20238-KResults of OperationsMar 13, 2023SC 13GSC 13GFeb 9, 2023SC 13GSC 13GFeb 8, 2023SC 13GSC 13GFeb 3, 20238-KMaterial AgreementJan 5, 20238-KExecutive ChangeDec 7, 202210-Q10-QNov 9, 20228-KResults of OperationsNov 9, 20228-KExecutive ChangeOct 12, 202210-Q10-QAug 11, 20228-KResults of OperationsAug 11, 2022
Insider Activity
In the 90 days to Mar 20, 2026: 8 sold $9.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 20, 2026 | Neervannan SeshadriChief Operating Officer | Sell | 2,989 | $66.75 | $200K |
| Mar 19, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sell | 11,964 | $67.00 | $802K |
| Mar 19, 2026 | Neervannan SeshadriChief Operating Officer | Sell | 4,589 | $67.00 | $307K |
| Mar 19, 2026 | Mottiwala AzizChief Commercial Officer | Sell | 4,440 | $67.00 | $297K |
| Mar 19, 2026 | Wahl BryanGeneral Counsel | Sell | 4,231 | $67.00 | $283K |
| Mar 19, 2026 | Whitfield Dianne C.Chief Human Resources Officer | Sell | 4,174 | $67.00 | $280K |
| Mar 19, 2026 | Farrow Jeffrey SSee Remarks | Sell | 2,186 | $67.00 | $146K |
| Mar 19, 2026 | Lin Elizabeth YeuChief Medical Officer | Sell | 390 | $67.00 | $26K |
| Mar 18, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sell | 11,667 | $68.71 | $802K |
| Mar 18, 2026 | Mottiwala AzizChief Commercial Officer | Sell | 4,330 | $68.71 | $298K |
| Mar 18, 2026 | Wahl BryanGeneral Counsel | Sell | 4,125 | $68.71 | $283K |
| Mar 18, 2026 | Whitfield Dianne C.Chief Human Resources Officer | Sell | 4,071 | $68.71 | $280K |
| Mar 18, 2026 | Neervannan SeshadriChief Operating Officer | Sell | 3,610 | $68.71 | $248K |
| Mar 18, 2026 | Farrow Jeffrey SSee Remarks | Sell | 2,133 | $68.71 | $147K |
| Mar 18, 2026 | Lin Elizabeth YeuChief Medical Officer | Sell | 379 | $68.71 | $26K |
| Mar 17, 2026 | Azamian Bobak R.President/CEO and Board Chair | Sell | 10,972 | $69.42 | $762K |
| Mar 17, 2026 | Mottiwala AzizChief Commercial Officer | Sell | 4,286 | $69.42 | $298K |
| Mar 17, 2026 | Wahl BryanGeneral Counsel | Sell | 4,084 | $69.42 | $284K |
| Mar 17, 2026 | Whitfield Dianne C.Chief Human Resources Officer | Sell | 4,029 | $69.42 | $280K |
| Mar 17, 2026 | Neervannan SeshadriChief Operating Officer | Sell | 3,125 | $69.42 | $217K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance